Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have identified a mechanism that protects the female brain from genetic diseases. Although one of the two X chromosomes is ...
A recent study led by UC Davis Health researchers provides new insights into the molecular changes linked to the rare genetic condition 22q11.2 deletion syndrome, or 22q. It found unique biomarkers ...
Researchers have identified a promising strategy to improve memory and brain cell function in models of 22q11.2 Deletion Syndrome. The study, published in eLife, shows that reducing the levels of the ...
Researchers have found that mitochondrial dysfunction in the blood-brain barrier (BBB) may lead to neuropsychiatric disease in some patients with DiGeorge syndrome. Changes in brain connectivity ...
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a ...
Zynerba Pharmaceuticals, Inc. ZYNE presented positive long-term 38-week data from the phase 2 INSPIRE trial with Zygel in children and adolescents with 22q11.2 deletion syndrome. The data were ...
PLYMOUTH MEETING, Pa., Dec. 5, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing ...
"22q11.2 Deletion Syndrome Market"22q11.2 Deletion Syndrome Companies are Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others. The United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results